Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Change in Account Payables (2016 - 2025)

Historic Change in Account Payables for Anika Therapeutics (ANIK) over the last 16 years, with Q3 2025 value amounting to $231000.0.

  • Anika Therapeutics' Change in Account Payables rose 10787.32% to $231000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$956000.0, marking a year-over-year increase of 1123.49%. This contributed to the annual value of -$2.5 million for FY2024, which is 2268181.82% down from last year.
  • Anika Therapeutics' Change in Account Payables amounted to $231000.0 in Q3 2025, which was up 10787.32% from -$1.1 million recorded in Q2 2025.
  • Over the past 5 years, Anika Therapeutics' Change in Account Payables peaked at $1.4 million during Q4 2022, and registered a low of -$2.9 million during Q3 2024.
  • In the last 5 years, Anika Therapeutics' Change in Account Payables had a median value of -$60000.0 in 2021 and averaged -$130894.7.
  • In the last 5 years, Anika Therapeutics' Change in Account Payables surged by 51500.0% in 2022 and then tumbled by 91172.41% in 2024.
  • Over the past 5 years, Anika Therapeutics' Change in Account Payables (Quarter) stood at -$398000.0 in 2021, then surged by 459.8% to $1.4 million in 2022, then dropped by 8.66% to $1.3 million in 2023, then plummeted by 109.25% to -$121000.0 in 2024, then soared by 290.91% to $231000.0 in 2025.
  • Its last three reported values are $231000.0 in Q3 2025, -$1.1 million for Q2 2025, and $47000.0 during Q1 2025.